<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00550563</url>
  </required_header>
  <id_info>
    <org_study_id>I 99207</org_study_id>
    <secondary_id>RPCI-I-99207</secondary_id>
    <nct_id>NCT00550563</nct_id>
  </id_info>
  <brief_title>DNA Changes That Affect Vitamin D Metabolism in Patients With Colorectal Cancer Receiving Vitamin D Supplements</brief_title>
  <official_title>Identification of 24-Hydroxylase Polymorphisms and Splicing Variants That Modulate Vitamin D Oxidative Metabolism and Serum Pharmacokinetics in Patients With Colorectal Cancer on Cholecalciferol Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help
      doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

      PURPOSE: This clinical trial is studying changes in DNA that affect vitamin D metabolism in
      patients with colorectal cancer receiving vitamin D supplements.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To identify CYP24 single nucleotide polymorphisms (SNPs) using peripheral blood
           mononuclear cell genomic DNA from patients with colorectal cancer receiving
           cholecalciferol supplementation.

        -  To evaluate the effects of these CYP24 SNPs on baseline serum vitamin D_3 metabolites
           (25-D_3, 24,25-D_3, and 1,25-D_3), and parathyroid hormone levels (PTH).

        -  To evaluate the effects of these CYP24 SNPs on serum vitamin D_3 metabolites and PTH
           levels during cholecalciferol treatment.

        -  To examine CYP24 splicing, protein expression, and enzyme activity at baseline and
           during cholecalciferol treatment.

        -  To determine the relationship, if any, between serum cholecalciferol pharmacokinetic
           parameters and CYP24 SNPs, splicing variants, and enzyme activity.

      OUTLINE: Patients receive oral cholecalciferol 2000 IU once daily for 1 year. Patients
      without response to vitamin D supplementation (serum 25-D_3 level &lt; 32 ng/mL) by 6 months
      will have their cholecalciferol dose increased to 4000 IU once daily.

      Blood is collected at baseline and on days 14, 30, 60, 90, 180, 270, and 360. Peripheral
      blood mononuclear cells for CYP24 genotyping, protein expression, enzyme activity, and
      splicing variants are analyzed by polymerase chain reaction (PCR), western blot, high
      performance liquid chromatography, and reverse transcriptase PCR, respectively. Serum is
      analyzed for vitamin D_3 metabolite levels (by radioimmunoassay), calcium (to monitor for
      hypercalcemia), and parathyroid hormone assays (to measure vitamin D effect).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of CYP24 single nucleotide polymorphisms (SNPs)</measure>
    <time_frame>Baseline, days 14, 30, 60, 90, 180, 270, 360</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of CYP24 SNPs on baseline serum vitamin D3 metabolites (25-D3, 24,25-D3, and 1,25-D3), and parathyroid hormone levels (PTH)</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of CYP24 SNPs on serum vitamin D3 metabolites and PTH levels during cholecalciferol treatment</measure>
    <time_frame>Baseline, days 14, 30, 60, 90, 180, 270, 360</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CYP24 splicing, protein expression, and enzyme activity at baseline and during cholecalciferol treatment</measure>
    <time_frame>Baseline, days 14, 30, 60, 90, 180, 270, 360</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relationship between serum cholecalciferol pharmacokinetic parameters and CYP24 SNPs, splicing variants, and enzyme activity</measure>
    <time_frame>Baseline, days 14, 30, 60, 90, 180, 270, 360</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Oral Cholecalciferol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral cholecalciferol 2000 IU once daily for 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>cholecalciferol</intervention_name>
    <description>Oral</description>
    <arm_group_label>Oral Cholecalciferol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <description>companion study</description>
    <arm_group_label>Oral Cholecalciferol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
    <description>companion study</description>
    <arm_group_label>Oral Cholecalciferol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
    <description>companion study</description>
    <arm_group_label>Oral Cholecalciferol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>reverse transcriptase-polymerase chain reaction</intervention_name>
    <description>companion study</description>
    <arm_group_label>Oral Cholecalciferol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>western blotting</intervention_name>
    <description>companion study</description>
    <arm_group_label>Oral Cholecalciferol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>high performance liquid chromatography</intervention_name>
    <description>companion study</description>
    <arm_group_label>Oral Cholecalciferol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>companion study</description>
    <arm_group_label>Oral Cholecalciferol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>companion study</description>
    <arm_group_label>Oral Cholecalciferol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <description>Additional therapy</description>
    <arm_group_label>Oral Cholecalciferol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>immunoscintigraphy</intervention_name>
    <description>additional testing</description>
    <arm_group_label>Oral Cholecalciferol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Prior or current documented diagnosis of colorectal cancer

               -  All stages

          -  25OH-D3 level &lt; 50 ng/mL

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Life expectancy &gt; 6 months

          -  Serum creatinine &lt; 2.0 mg/dL

          -  Serum bilirubin &lt; 2.0 mg/dL

          -  No prior or current hypercalcemia (defined as albumin corrected serum calcium &lt; 10.2
             mg/dL)

          -  No known contraindication for vitamin D supplementation

          -  No genitourinary stones within the past 5 years

          -  No severe comorbid conditions such as uncompensated heart failure or active infection

        PRIOR CONCURRENT THERAPY:

          -  No supplemental vitamin D beyond what is provided through the study

          -  At least 2 months since prior vitamin D supplementation exceeding 800 International
             Units (IU)

               -  Nondietary vitamin D supplements should not have exceeded 800 IU/day within the
                  past 2 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marwan Fakih, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2007</study_first_submitted>
  <study_first_submitted_qc>October 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2007</study_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage I colon cancer</keyword>
  <keyword>stage II colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage I rectal cancer</keyword>
  <keyword>stage II rectal cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

